AbbVie 2014 Annual Report Download - page 140
Download and view the complete annual report
Please find page 140 of the 2014 AbbVie annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.-
1 -
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11
-
12
-
13
-
14
-
15
-
16
-
17
-
18
-
19
-
20
-
21
-
22
-
23
-
24
-
25
-
26
-
27
-
28
-
29
-
30
-
31
-
32
-
33
-
34
-
35
-
36
-
37
-
38
-
39
-
40
-
41
-
42
-
43
-
44
-
45
-
46
-
47
-
48
-
49
-
50
-
51
-
52
-
53
-
54
-
55
-
56
-
57
-
58
-
59
-
60
-
61
-
62
-
63
-
64
-
65
-
66
-
67
-
68
-
69
-
70
-
71
-
72
-
73
-
74
-
75
-
76
-
77
-
78
-
79
-
80
-
81
-
82
-
83
-
84
-
85
-
86
-
87
-
88
-
89
-
90
-
91
-
92
-
93
-
94
-
95
-
96
-
97
-
98
-
99
-
100
-
101
-
102
-
103
-
104
-
105
-
106
-
107
-
108
-
109
-
110
-
111
-
112
-
113
-
114
-
115
-
116
-
117
-
118
-
119
-
120
-
121
-
122
-
123
-
124
-
125
-
126
-
127
-
128
-
129
-
130 -
131 -
132 -
133 -
134 -
135 -
136 -
137 -
138 -
139 -
140 -
141 -
142 -
143 -
144 -
145 -
146 -
147 -
148 -
149 -
150 -
151
-
152
-
153
-
154
-
155
-
156
-
157
-
158
-
159
-
160
-
161
-
162
-
163
-
164
-
165
-
166
-
167
-
168
-
169
-
170
-
171
-
172
-
173
-
174
-
175
-
176
-
177
-
178
-
179
-
180
-
181
-
182
 |
 |
17MAR201515325913
13NOV201221352027
I. Executive Summary
Compensation Philosophy
At AbbVie, the board believes a well-designed compensation program should align executive interests with the
drivers of profitable growth and shareholder returns, support achievement of the company’s primary business goals, and
attract and retain world-class executives whose talents and contributions sustain the growth in long-term stockholder
value. Consequently, the board believes the substantial majority of NEO compensation at AbbVie should be performance-
based.
Business Overview
AbbVie is a global, research-based biopharmaceutical company that develops and markets advanced therapies for
some of the world’s most complex and serious diseases. Our products support the treatment of conditions such as
chronic autoimmune disease (including rheumatoid arthritis, psoriasis, and Crohn’s disease), hepatitis C virus (HCV),
human immunodeficiency virus (HIV), endometriosis, thyroid disease, Parkinson’s disease, complications associated with
cystic fibrosis, and other health conditions. Our pipeline includes more than 40 compounds or indications in development
across important medical specialties such as immunology, virology/liver disease, oncology, renal disease, neurological
diseases, and women’s health.
Business Performance Highlights
2014 was a very successful year for AbbVie financially and operationally and in our pipeline development efforts.
AbbVie continued to deliver on our commitment to stockholders in 2014 by growing our sales and earnings and
delivering top quartile returns. The measures set forth below were calculated as of December 31, 2014.
7.1% Adjusted operaonal sales growth vs. 2013*
Delivered growth a year ahead of schedule
22.5% Increase in quarterly dividend since AbbVie launch
Raised quarterly dividend to $0.49 per share from $0.40 per share at separaon
$49BN Increase in market cap since AbbVie launch
Added significant stockholder value with a market cap over $100 billion
105.7% 2-year total shareholder return since 2013 incepon
28% total shareholder return in 2014
5.7% Adjusted earnings per share growth vs. 2013*
Significantly outperformed original guidance to deliver 2014 adjusted EPS of $3.32/share
40+ Acve clinical development programs
Most robust pipeline in company history
*Adjusted sales and adjusted earnings per share are reported and reconciled in our
Form 8-K dated January 30, 2015.
20 2015 Proxy Statement
EXECUTIVE COMPENSATION